Prof. Dr. Claudio De Simone & Next Gen Pharma India Pvt. Ltd. v. Actial Farmaceutica Srl. (Formerly known as CD Investment Srl.) & Ors.

Every founder dreams of inventing something so valuable that no one else can touch it. But what happens when the legal shield protecting your invention disappears? The dispute over the De Simone Formulation is a cautionary tale about the limits of trade secret protection once a patent has expired and an invention has entered the public domain. For startups and IP professionals, this case is a masterclass in why your IP strategy cannot rely on a single pillar.

The plaintiffs, Prof. Dr. Claudio De Simone and an associate, claimed ownership over a proprietary probiotic composition known as the 'De Simone Formulation.' Their rights, they argued, originated from patent protection and were later preserved through a series of Know-How agreements with the defendants, who operated under the umbrella of the CD Group entities. The defendants, including Actial Farmaceutica Srl., were the commercial counterparties who had worked with the formulation over the years. The relationship began with valid patent protection, but that protection came with an expiration date. When the underlying patent expired in 2015, the legal landscape shifted dramatically, setting the stage for a confrontation over who could manufacture, sell, and profit from the formulation.

The plaintiffs argued that even though the patent had expired, they still retained proprietary rights over the De Simone Formulation through the Know-How agreements and the doctrine of trade secrets. In their view, the confidential and technical knowledge embedded in the formulation remained their exclusive property, and the defendants had no right to work or sell it without their authorization. The defendants countered that once the patent expired, the invention entered the public domain. They argued that any contractual Know-How obligations could not create a new monopoly where patent law had deliberately ended one. The legal friction was clear: could private contractual arrangements extend proprietary control over an invention that the patent system had deliberately released to the world?

The court sided with the defendants and dismissed the suit. The court reasoned that without a valid patent right in India, the plaintiffs lacked a personal cause of action to restrain the defendants from working or selling the formulation. The court held that the plaintiffs' claims, rooted in Know-How and trade secrets, did not constitute an individual civil right capable of blocking the defendants' commercial activities once the patent had expired. In effect, the court drew a firm line: patent law defines the boundaries of exclusivity, and once those boundaries expire, contractual Know-How alone cannot resurrect them against the public interest.

For founders and IP professionals, the lesson is stark: never treat a patent and a trade secret as interchangeable safety nets. If your invention is protectable by patent, file early, maintain it diligently, and plan strategically for the day it expires. Know-How agreements are valuable tools during the patent term and for genuinely secret processes, but they are not a substitute for patent protection once exclusivity ends. Build a layered IP strategy, anticipate the post-expiration landscape, and understand that once an invention enters the public domain, the law favors competition over private restriction.